Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
The present invention provides a method for treating alopecia using certain pharmaceutically active pyrrolo[2,3-d]pyrimidinyl acrylamides having the structure: or a pharmaceutically acceptable salt thereof, as set forth in the Description.
1. A method for treating alopecia by administering to a mammal in need a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, and wherein
R 2 is selected from the group consisting of hydrogen, deuterium, C 1 -C 6 linear or branched chain alkyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, monocyclic or bicyclic heteroaryl, comprising 5- and/or 6-membered rings, (aryl)C 1 -C 6 linear or branched chain alkyl, (heteroaryl)C 1 -C 6 linear or branched chain alkyl, (heterocyclic)C 1 -C 6 linear or branched chain alkyl, (C 1 -C 6 linear or branched chain alkyl)aryl, (C 1 -C 6 linear or branched chain alkyl)heteroaryl, (C 1 -C 6 linear or branched chain alkyl)heterocyclic, C 1 -C 6 linear or branched chain perfluoroalkyl, C 1 -C 6 linear or branched chain alkoxy, C 1 -C 6 linear or branched chain perfluoroalkoxy, halogen, cyano, hydroxyl, amino, carboxy, aminocarbonyl, (C 1 -C 6 linear or branched chain alkyl)aminocarbonylamino, (C 1 -C 6 linear or branched chain alkyl)aminocarbonyl, —SOR 12 , —SO 2 R 12 , —NR 13 SO 2 R 12 , —SO 2 NR 13 R 14 , and —NR 13 SO 2 NR 14 R 15 ; where said alkyl, aryl and heteroaryl is independently optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, cyano, alkylamino, dialkylamino, CF 3 , aminocarbonyl, (C 1 -C 6 linear or branched chain alkyl)aminocarbonyl, and C 3 -C 6 cycloalkyl;
R 3 is selected from the group consisting of hydrogen, deuterium, C 1 -C 6 linear or branched chain alkyl, C 1 -C 6 linear or branched chain perfluoroalkyl, halogen, and cyano;
R a , R b , R c and R d are independently selected from hydrogen, C 1 -C 6 linear or branched chain alkyl, C 1 -C 6 linear or branched chain perfluoroalkyl, aryl, alkylaryl, (aryl)C 1 -C 6 linear or branched chain alkyl, (heteroaryl)C 1 -C 6 linear or branched chain alkyl, heteroaryl, halogen, cyano, hydroxyl, C 1 -C 6 linear or branched chain alkoxy, amino, carboxy, aminocarbonyl, (heterocyclic)C 1 -C 6 linear or branched chain alkyl, (C 1 -C 6 linear or branched chain alkyl)aryl, (C 1 -C 6 linear or branched chain alkyl)heteroaryl, and (C 1 -C 6 linear or branched chain alkyl)heterocyclic, where said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, alkylamino, dialkylamino, CF 3 , and C 3 -C 6 cycloalkyl;
R 0 , R 1 , R 4 , R 6 , R 8 , R 9 and R 10 are independently selected from hydrogen, C 1 -C 6 linear or branched chain alkyl, C 1 -C 6 linear or branched chain perfluoroalkyl, C 6 -C 10 aryl, monocyclic or bicyclic heteroaryl, comprising 5- and/or 6-membered rings, (aryl)C 1 -C 6 linear or branched chain alkyl, (heteroaryl)C 1 -C 6 linear or branched chain alkyl, heteroaryl, halogen, cyano, hydroxyl, C 1 -C 6 linear or branched chain alkoxy, amino, carboxy, aminocarbonyl, (heterocyclic)C 1 -C 6 linear or branched chain alkyl, (C 1 -C 6 linear or branched chain alkyl)aryl, (C 1 -C 6 linear or branched chain alkyl)heteroaryl, and (C 1 -C 6 linear or branched chain alkyl)heterocyclic, where said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, alkylamino, dialkylamino, CF 3 , and C 3 -C 6 cycloalkyl; where, alternatively, R 0 or R 1 , and/or R 6 , respectively together with either of R 4 , R a , R b , R c or R d , may independently form a bond or a C 1 -C 6 linear alkyl chain; and/or, alternatively, R 4 , respectively together with either of R a , R b , R c or R d , may independently form a bond or a C 1 -C 6 linear alkyl chain; and/or, alternatively, R 8 and R 9 may together form a 3-6-membered ring optionally containing one or two O or N atoms;
R 11 is hydrogen or deuterium; and,
R 12 , R 13 , R 14 and R 15 are independently selected from hydrogen, C 1 -C 6 linear or branched chain alkyl, C 1 -C 6 linear or branched chain perfluoroalkyl, C 6 -C 10 aryl, alkylaryl, and (aryl)C 1 -C 6 linear or branched chain alkyl.
2. A method for treating alopecia by administering to a mammal in need a therapeutically effective amount of the compound 1-((2S,5R)-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-2-methylpiperidin-1-yl)prop-2-en-1-one, or a pharmaceutically acceptable salt thereof.